Cancer Treatment Side Effect – Caphosol(R), New Therapy For The Prevention And Treatment Of Oral Mucositis Is Launched Today

January 29, 2009 at 11:00 am Leave a comment


EUSA Pharma announced the launch of Caphosol, a
medical innovation for the prevention and treatment of oral mucositis. Oral mucositis is one of the
most common and debilitating side effects of cancer treatment 1 caused by radiotherapy or
chemotherapy and affects approximately 115,000 people a year in the UK.2



In a double-blind, prospective, randomised clinical trial of 95 patients undergoing bone marrow
transplantation (BMT) following radiotherapy or chemotherapy, more than twice as many patients
in the Caphosol treatment group avoided oral mucositis altogether and duration of the symptoms
was halved. In the Caphosol group patients used 72% less morphine for the pain and nearly 75%
required no morphine at all.3



“It is extremely frustrating having to watch my cancer patients go through the pain and discomfort
of oral mucositis, particularly as it is a predictable complication. Preventing its development in the
first place would allow us to avoid treatment interruptions that can lengthen in-patient stay and
may compromise delivery of treatment in a timely fashion” said Professor Charlie Craddock,
Consultant Haematologist, University Hospitals Birmingham NHS Foundation Trust.



Oral mucositis affects virtually all patients receiving radiation therapy for head and neck cancer1,
more than 70 per cent of patients undergoing bone marrow transplantation (BMT) and 40 per
cent of patients who receive conventional chemotherapy.4 The economic impact of mucositis can
be significant, as the need for prolonged hospital stays, nutritional therapy and treatments for
pain and infection can drive up the costs of therapy. In severe cases, the costs of cancer care for
oral mucositis patients can more than double.5



Oral mucositis is an inflammation of the mucous membranes of the mouth with symptoms ranging
from redness to severe ulceration of mucosal tissues. It can limit patients’ ability to eat or swallow
as well as causing severe pain that can require the use of opioid analgesics like morphine and may ultimately require hospitalisation.3 Oral mucositis can also have implications on cancer care,
such as reductions in dose and/or duration of radiotherapy,5 as well as treatment delays5 and is
associated with a higher risk of infection in patients that are already immunocompromised.6
Caphosol is a mouth rinse consisting of a supersaturated calcium and phosphate solution.



The primary ingredients, calcium and phosphate play crucial roles in maintaining a healthy oral cavity.
Calcium has an important role in tissue repair while phosphate is a key building block of the
mucosal lining3, helps maintain the pH balance, reducing the risk of bacterial overgrowth and
helps maintain dental structure.7 Caphosol is convenient and easy to use and can be used at
home, without medical supervision.



“Caphosol is a much needed therapeutic advance for a distressing and painful condition that can
be prevented” said Dr Morgan, Medical Director at EUSA Pharma. “Caphosol is the result of
EUSA’s commitment to the research and development of treatments in oncology.”



About Caphosol



CAPHOSOL is an advanced electrolyte solution indicated in Europe as an adjunct to standard oral care for
the prevention and treatment of oral mucositis caused by radiation or high dose chemotherapy. Relief of
dryness of the oral mucosa in these conditions is associated with an amelioration of pain. CAPHOSOL, a
patented prescription medical device, is also indicated for dryness of the mouth or throat (hyposalivation,
xerostomia), regardless of the cause or whether the conditions are temporary or permanent. Patients
restricted to a low sodium diet should consult their physician before use. Patients should avoid eating or
drinking for at least 15 minutes after use.



About EUSA Pharma



EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on oncology,
pain control and critical care. The company currently has three products on the UK market, including
Caphosol for the prevention and treatment of oral mucositis, a common and debilitating side-effect of
radiation therapy and high dose chemotherapy, Erwinase® for the treatment of acute lymphoblastic
leukaemia, and Collatamp® EG a surgical implant impregnated with the antibiotic gentamicin.
Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors.
Since its foundation, the company has completed several significant transactions, including the acquisitions
of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the
European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth
strategy the company has established infrastructure in the US, a pan-European presence covering over 20
countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its
rapid growth within its specialist areas of medical and geographic focus.



http://www.eusapharma.com



References




1. Sonis ST. J Support Oncol. 2007;5(suppl 4):3-11


2. EUSA Pharma Data on file


3. Papas A, Clark RE et al. Bone Marrow Transplant 2003;31:705-712


4. Köstler WJ, Hejna M, Wenzel C, Zielinski CC. CA Cancer J Clin. 2001;51:290-315


5. Sonis ST, J Support Oncol 2004;2 (suppl.3):3-8


6. Treister NS, Woo SB. Chemotherapy induced oral mucositis. eMedicine October 2008


7. De Almeida PDV, Grégio AMT, Machado MÂN, et al. J Contemp Dent Pract. 2008;9:72-80



EUSA Pharma

[Via http://www.medicalnewstoday.com]

Advertisements

Entry filed under: Uncategorized.

Winning The War On Cancer: The Critical Role Of Radiation Oncology Orlando-Based Health Initiative Wins National Award For HIV Prevention And Continuum Of Care To Individuals

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed


Archives

Top Clicks

  • None

Blog Stats

  • 15,535 hits

%d bloggers like this: